BACKGROUND Asymptomatic left ventricular (LV) dysfunction is highly prevalent in type 2 diabetes patients. Unlike the other hypoglycemic drugs, SGLT2 inhibitors have shown potential benefits for reducing cardiovascular death and risk factors, aside from lowering plasma glucose levels. With this study we aim at determining whether the treatment with empagliflozin is associated with an improvemen...

Considering the pathophysiology of T2D, insulin is inevitable for some patients. However, there are limitations with injection therapy in T2D patients, such as a lack compliance to perform injection, increased likelihood hypoglycemia and difficulty achieving target glycemic levels, lowered quality life. To directly compare long-term effectiveness safety sodium glucose co-transporter 2 (SGLT2) i...

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a newly approved class of glucose-lowering medications with a novel mechanism of action. These agents increase glycosuria, which leads to improved glucose control. They also produce an osmotic diuresis that, in part, contributes to blood pressure reduction and calorie loss secondary to glycosuria leading to weight loss (1,2). A recent review...

The article by Raut and Maheshwari[1] is indeed interesting. However, the suggestion made by the authors on the usefulness of empagliflozin in diabetic perioperative patients needs contemplation from the point of patient safety and risk factors, as it causes euglycaemic diabetic ketoacidosis. Moreover, in May 2015, the Food and Drug Administration issued a warning of ketoacidosis with the use o...

Eighty-six patients with type 2 diabetes (HbA1c = 7.86 0.8% [62 6 9 mmol/mol], estimated glomerular filtration rate [eGFR] = 89 6 19 mL · min · 1.73 m) received empagliflozin (25 mg/day) for 90 weeks with frequent (n = 11) assessments of body weight, eGFR, and fasting plasma glucose (FPG). Time-dependent glucose filtration was calculated as the product of eGFR and FPG; time-dependent glycosuria...

Aim. To evaluate the cost-effectiveness of empagliflozin therapy in patients with heart failure (HF) across ejection fraction (EF) range Russian Fe­­deration. Material and methods. An analysis cost HF management was carried out an analytical decision-making model built MS Excel, which makes it possible estimating costs from state position. Results. Taking into account direct adverse events, as ...